

# FIRST LIGHT

## RESEARCH

### BOB Economics Research | WPI

WPI inflation accelerates, peak in Q1

### Infosys | Target: Rs 1,540 | +10% | ADD

FY22 guidance in line; first signs of supply pressure

### Wipro | Target: Rs 470 | +9% | ADD

Good execution; FY22 guidance robust

## SUMMARY

### India Economics: WPI

WPI accelerated to 7.4% in Mar'21 from 4.2% in Feb'21 led by broad based increase in food, fuel and manufactured products inflation. A low base effect and rising global commodity prices imply there is room for WPI inflation to go up. Further, localized lockdowns can push food inflation higher. We expect WPI to average at 7% in FY22 with upside risks emanating from higher global commodity and oil prices and now a weaker INR. RBI to first increase reverse repo rate in H2FY22 and then repo rate in early FY23.

[Click here for the full report.](#)

### Infosys

Infosys' (INFO) Q4FY21 revenue growth of 2% CC QoQ was in line with our estimate of 1.9%, with the company also posting robust TCV of US\$ 2.1bn. Management has guided for 12-14% CC growth in FY22, on par with our estimates. FY22 EBIT margin guidance of 22-24% appears to bake in some supply pressure which is already evident in the sharp uptick in Q4 attrition. We raise FY22/FY23 EPS by 4.2%/0.2% and retain our target P/E at 26x. On rollover, we have a new Mar'22 TP of Rs 1,540 (vs. Rs 1,500). Retain ADD.

[Click here for the full report.](#)

## TOP PICKS

### LARGE-CAP IDEAS

Company	Rating	Target
<a href="#">Cipla</a>	Buy	1,000
<a href="#">TCS</a>	Buy	3,780
<a href="#">Tech Mahindra</a>	Buy	1,130

### MID-CAP IDEAS

Company	Rating	Target
<a href="#">Alkem Labs</a>	Buy	3,750
<a href="#">Greenply Industries</a>	Buy	195
<a href="#">Laurus Labs</a>	Buy	480
<a href="#">Transport Corp</a>	Buy	330

Source: BOBCAPS Research

## DAILY MACRO INDICATORS

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	1.64	0bps	12bps	94bps
India 10Y yield (%)	6.01	(1bps)	(19bps)	(47bps)
USD/INR	75.14	0.3	(2.5)	2.0
Brent Crude (US\$/bbl)	66.25	4.1	(9.6)	100.0
Dow	33,731	0.2	4.0	42.5
Shanghai	3,417	0.6	0.4	22.1
Sensex	48,544	1.4	(2.8)	59.2
India FII (US\$ mn)	9 Apr	MTD	CYTD	FYTD
FII-D	(94.3)	(407.0)	(2,434.3)	(407.0)
FII-E	(81.1)	44.4	7,370.7	44.4

Source: Bank of Baroda Economics Research

### BOBCAPS Research

research@bobcaps.in



## Wipro

Wipro (WPRO) delivered an upbeat QoQ performance in Q4FY21 with 3% CC revenue growth, ahead of our estimate of 2.6%. Growth was driven by BFSI, ENU, hi-tech and retail. Operating margin at 21% also came in above expectations. TCV was robust at US\$ 1.4bn and included 12 large deals. We increase FY22/FY23 EPS by 7.5%/4.5% factoring in the Q4 performance, management's guidance and a strong deal pipeline. Reiterate ADD as we raise our Mar'22 TP to Rs 470 (vs. Rs 450) based on an unchanged 18.8x P/E.

[Click here for the full report.](#)

## WHOLESALE INFLATION

15 April 2021

### WPI inflation accelerates, peak in Q1

**WPI accelerated to 7.4% in Mar'21 from 4.2% in Feb'21 led by broad based increase in food, fuel and manufactured products inflation. A low base effect and rising global commodity prices imply there is room for WPI inflation to go up. Further, localized lockdowns can push food inflation higher. We expect WPI to average at 7% in FY22 with upside risks emanating from higher global commodity and oil prices and now a weaker INR. RBI to first increase reverse repo rate in H2FY22 and then repo rate in early FY23.**

Sameer Narang

Jahnvi | Dipanwita Mazumdar

chief.economist@bankofbaroda.com

**Food inflation accelerates:** Food inflation rose to a 5-month high of 5.3% in Mar'21 from 3.3% in Feb'21. This was led by jump in fruits and vegetables index to 4% in Mar'21 from 2.2% in Feb'21 on the back of acceleration in fruit prices (19-month high) to 16.3% in Mar'21 (9.5% in Feb'21). Tomato prices are up by 4.7% versus 3.4% in Feb'21. Prices of protein-based items too rose sharply to 5.4% in Mar'21 with egg prices skyrocketing to 5-month high of 19.9% in Mar'21. The decline in cereal prices moderated to 4.1% versus 6.6% in Feb'21 on the back of a 7.8% decline in wheat prices versus dip of 10.6% in Feb'21. Prices of pulses too edged upwards to 13% in Mar'21 from 10.2% in Feb'21.

**Fuel and power inflation noted sharp uptick:** Fuel and power inflation rose steeply by 10.3% in Mar'21 from 0.6% in Feb'21. This was led by mineral oil index which rose by 18% in Mar'21 from 0.9% in Feb'21 driven by base effect (index was - 8.7% in Mar'20 as against 1.1% in Feb'20). Petrol index increased by 18.5% (0.8% in Feb'21), HSD by 18.3% (from -0.1%), LPG by 10.3% (from 0.5%) and Naptha by 30.2% (from 2.4%). International oil prices rose to US\$ 65.7/bb in Mar'21 from US\$ 62/bbl in Feb'21. Mineral oil index during Apr-Dec FY21 was 20.4% below Apr-Dec FY20 levels. Thus we expect much sharper increase in coming months at these oil price levels.

**Core inflation solidifies:** Core inflation rose to its highest level in 2011-12 series at 7% in Mar'21 from 5.5% in Feb'21. Manufactured products inflation rose by ~150bps to 7.3% in Mar'21 from 5.8% in Feb'21. Of the 22 commodities, prices of 12 commodities rose, with basic metals, rubber, food and chemical products taking the lead. With international commodity prices firming up another 1% in Apr'21, we expect manufactured product inflation to remain elevated. Restrictions in India and opening up of global economy point to supply demand imbalance building up of which may drive inflation higher.



**ADD**  
 TP: Rs 1,540 | ▲ 10%

**INFOSYS**

| IT Services

| 15 April 2021

## FY22 guidance in line; first signs of supply pressure

**Infosys' (INFO) Q4FY21 revenue growth of 2% CC QoQ was in line with our estimate of 1.9%, with the company also posting robust TCV of US\$ 2.1bn. Management has guided for 12-14% CC growth in FY22, on par with our estimates. FY22 EBIT margin guidance of 22-24% appears to bake in some supply pressure which is already evident in the sharp uptick in Q4 attrition. We raise FY22/FY23 EPS by 4.2%/0.2% and retain our target P/E at 26x. On rollover, we have a new Mar'22 TP of Rs 1,540 (vs. Rs 1,500). Retain ADD.**

Ruchi Burde | Seema Nayak

research@bobcaps.in


**Performance in line:** INFO grew 2.8% USD/2% CC QoQ in Q4FY21, broadly in keeping with our estimates of 2.5% USD/1.9% CC. Growth was backed by momentum across verticals, especially manufacturing/retail/BFSI which were up 6.1%/3.5%/2.4% QoQ, USD. TCV at US\$ 2.1bn declined 70% QoQ due to the large Daimler deal win in Q3FY21, while rising 28% YoY. EBIT margin at 24.5% (est. 23.8%) fell 94bps QoQ owing to compensation hikes. As expected, attrition shot up to 15.2% (vs. 10% in Q3FY21), indicating supply pressure.

Ticker/Price	INFO IN/Rs 1,397
Market cap	US\$ 79.2bn
Shares o/s	4,258mn
3M ADV	US\$ 146.2mn
52wk high/low	Rs 1,478/Rs 604
Promoter/FPI/DII	13%/35%/52%

Source: NSE

**BFSI leads demand uptick:** Financial services showed industry-leading growth due to increased demand from areas such as customer experience, mortgage operations, end-to-end digital transformation and call centre technology. Despite continued weakness in a few retail subsegments, management is optimistic that the vertical will bounce back in FY22. In manufacturing, automotive is improving but aerospace could take longer to recover.

## STOCK PERFORMANCE



Source: NSE

**FY22 guidance matches estimates:** New FY22 growth guidance of 12-14% CC is in line with our estimates, based on a strong deal pipeline. With costs returning as the Covid-19 impact recedes and supply pressure rising, management has guided for FY22 operating margin in the range of 22-24%, which also matches our estimates.

## KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21P	FY22E	FY23E
Total revenue (Rs mn)	826,760	907,910	1,004,730	1,201,038	1,358,040
EBITDA (Rs mn)	208,890	222,680	279,350	323,051	356,654
Adj. net profit (Rs mn)	154,100	167,350	196,630	233,906	248,365
Adj. EPS (Rs)	35.4	39.0	46.1	55.6	59.0
Adj. EPS growth (%)	(4.0)	10.3	18.2	20.4	6.2
Adj. ROAE (%)	24.5	26.5	27.6	30.4	30.3
Adj. P/E (x)	39.5	35.8	30.3	25.1	23.7
EV/EBITDA (x)	27.5	25.9	20.7	17.7	16.2

Source: Company, BOBCAPS Research



**ADD**  
 TP: Rs 470 | ▲ 9%

**WIPRO**

| IT Services

| 15 April 2021

**Good execution; FY22 guidance robust**

Wipro (WPRO) delivered an upbeat QoQ performance in Q4FY21 with 3% CC revenue growth, ahead of our estimate of 2.6%. Growth was driven by BFSI, ENU, hi-tech and retail. Operating margin at 21% also came in above expectations. TCV was robust at US\$ 1.4bn and included 12 large deals. We increase FY22/FY23 EPS by 7.5%/4.5% factoring in the Q4 performance, management’s guidance and a strong deal pipeline. Reiterate ADD as we raise our Mar’22 TP to Rs 470 (vs. Rs 450) based on an unchanged 18.8x P/E.

Ruchi Burde | Seema Nayak  
 research@bobcaps.in

**Strong broad-based growth:** WPRO reported 3.9% USD/3% CC QoQ revenue growth vs. 3% USD/2.6% CC estimated, landing in the high end of the guided range of 1.5-3.5% QoQ CC for Q4FY21. TCV was reported at US\$ 1.4bn (vs. US\$ 1.2bn in Q3, up 16.7% QoQ), of which a significant portion represents net new contracts. Growth was helped by technology at 10.5% along with retail/energy & utilities (ENU)/BFSI at 7.7%/4.7%/3.9% QoQ, USD. BFSI demand is on the rise and manufacturing is recovering while ENU remains volatile. Both healthcare and manufacturing saw sequential weakness.

Ticker/Price	WPRO IN/Rs 431
Market cap	US\$ 32.5bn
Shares o/s	5,661mn
3M ADV	US\$ 75.8mn
52wk high/low	Rs 467/Rs 174
Promoter/FPI/DII	74%/9%/17%

Source: NSE

**Margin gains to sustain partially:** IT services EBIT margin was at 21% (-60bps QoQ), above our estimate of 17.6% due to cost optimisation from higher offshoring, utilisation and automation – the beat occurred despite salary hikes and INR appreciation, indicating some structural margin gains. Gross utilisation and offshore revenue share were the highest ever at 76.7% and 54.5% respectively.

**STOCK PERFORMANCE**



Source: NSE

**Healthy FY22 guidance:** With the five-year deal from Telefonica, the large Metro-AG deal (ramping up from Q1FY22) and a robust overall pipeline, management is confident of achieving 2-4% CC QoQ growth in Q1, ex-Capco. Salary increases and promotion cycles will be carried out in Q1 for 20% of the remaining employees, which will impact the margin.

**KEY FINANCIALS**

Y/E 31 Mar	FY19A	FY20A	FY21P	FY22E	FY23E
Total revenue (Rs mn)	589,060	613,401	622,425	752,966	875,308
EBITDA (Rs mn)	121,661	124,867	144,560	151,783	189,034
Adj. net profit (Rs mn)	90,074	95,295	108,783	111,565	137,020
Adj. EPS (Rs)	14.9	16.7	19.2	20.2	24.8
Adj. EPS growth (%)	12.3	11.6	15.2	5.1	22.8
Adj. ROAE (%)	17.1	16.9	19.5	18.5	20.6
Adj. P/E (x)	28.8	25.8	22.4	21.3	17.4
EV/EBITDA (x)	20.8	19.7	16.4	15.6	12.4

Source: Company, BOBCAPS Research



## Disclaimer

### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**ADD** – Expected return from >+5% to +15%

**REDUCE** – Expected return from -5% to +5%

**SELL** – Expected return <-5%

**Note:** Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Rating distribution

As of 31 March 2021, out of 88 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 42 have BUY ratings, 13 have ADD ratings, 5 are rated REDUCE and 28 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such.

Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### **Other disclosures**

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.